In Re (#03 March 2016)

First-of-a-kind Patent Litigation: Biosimilars

Oleksandr S. Mamunya, Nataliya A. Dryuk

Over the past few decades, biologicdrugs have revolutionizedtreatment for many conditions, includingthose that had not respondedto other treatment. Biologic drugscontain active substances of biologicalorigin obtained through productionfrom biological source and onmany occasions can bring more targetedeffect than traditional chemicallyderived small-molecule drugs.No wonder that biological drugslead the charts of best-selling drugsin the world and their sales groweach year. However, while bringinggreat advantages for patients, biologicsare often expensive in termsof cost per dose…

 

The abstract/extract view of this article is free. Access to the full text of this article requires a subscription.

Please send subscription inquiries by:

Phone: +380 44 495-27-27
E-mail: subscribe@ujbl.info

Subscribe
The Ukrainian Journal of Business Law

Subscribe to The Ukrainian Journal of Business Law right now and enjoy the most relevant issues on doing business in Ukraine on your device or in print.

All this for just USD 9.99 a month.

 

Subscribe now